RadNet (RDNT) Projected to Post Quarterly Earnings on Monday

RadNet (NASDAQ:RDNT - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $442.98 million for the quarter. RadNet has set its FY 2025 guidance at EPS.

RadNet (NASDAQ:RDNT - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.01. RadNet had a positive return on equity of 4.29% and a negative net margin of 0.25%. The firm had revenue of $477.10 million during the quarter, compared to analyst estimates of $459.42 million. On average, analysts expect RadNet to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

RadNet Price Performance

RDNT traded up $0.42 during trading on Monday, hitting $53.80. The company's stock had a trading volume of 86,717 shares, compared to its average volume of 663,001. The firm has a market capitalization of $4.04 billion, a price-to-earnings ratio of -766.69 and a beta of 1.59. RadNet has a twelve month low of $45.00 and a twelve month high of $93.65. The business's fifty day simple moving average is $50.80 and its 200 day simple moving average is $63.80. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.89.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Truist Financial decreased their price objective on shares of RadNet from $88.00 to $74.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Raymond James upgraded RadNet from an "outperform" rating to a "strong-buy" rating and lowered their price objective for the stock from $85.00 to $65.00 in a report on Wednesday, March 5th. StockNews.com upgraded RadNet to a "sell" rating in a research note on Wednesday, March 19th. Barclays decreased their price objective on RadNet from $74.00 to $60.00 and set an "overweight" rating on the stock in a report on Monday, March 24th. Finally, Jefferies Financial Group decreased their price target on shares of RadNet from $100.00 to $80.00 and set a "buy" rating on the stock in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $69.75.

Insider Activity at RadNet

In related news, COO Norman R. Hames sold 5,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $49.79, for a total transaction of $248,950.00. Following the completion of the sale, the chief operating officer now directly owns 261,959 shares of the company's stock, valued at approximately $13,042,938.61. This trade represents a 1.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cornelis Wesdorp sold 1,000 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $50.52, for a total transaction of $50,520.00. Following the completion of the transaction, the chief executive officer now directly owns 55,995 shares in the company, valued at $2,828,867.40. The trade was a 1.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,000 shares of company stock valued at $1,926,730. 5.12% of the stock is owned by company insiders.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.